Evidence map›Paper›PMID 39774657›Full record

Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2025

Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial.

Wenxin Zhang, Simon B Ascher, Sudipto Dolui, Ilya M Nasrallah, Yuan Lu, Julia Neitzel, Estefania Toledo, Lidia Glodzik, Hossam A Shaltout, Timothy M Hughes and 2 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenxin ZhangDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Simon B AscherKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California San Francisco, San Francisco, California, USA.
Sudipto DoluiDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ilya M NasrallahDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Yuan LuCenter for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA.
Julia NeitzelDepartment of Radiology and Nuclear Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.
Estefania ToledoDepartment of Preventive Medicine and Public Health, University of Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Lidia GlodzikDepartment of Radiology, Brain Health Imaging Institute, Weill Cornell Medicine, New York, New York, USA.
Hossam A ShaltoutHypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Timothy M HughesDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Jarett D BerryDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, Texas, USA (Medical Sciences Section).
Yuan MaDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Funding

Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages for Everyone's Health (CLE Health)UM1TR004528 · CASE WESTERN RESERVE UNIVERSITY · 2025 to 2025
$7.9M
UC Davis Clinical and Translational Science CenterUL1TR001860 · UNIVERSITY OF CALIFORNIA AT DAVIS · 2025 to 2025
$5.1M
Institutional Career Development Core (KL2)KL2TR001859 · UNIVERSITY OF CALIFORNIA AT DAVIS · 2025 to 2025
$1.2M
Epidemiologic, imaging and pathological studies of the role of blood pressure variability in dementia etiologyR00AG071742 · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2025 to 2025
$227k
Characterization of Mechanisms of Exercise Intolerance in Patients at Risk for Heart Failure with Preserved Ejection FractionK24HL166681 · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · 2025 to 2025
$115k
NCATS NIH HHS KL2 TR001859NCATS NIH HHS UL1 TR000002NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR000050NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR000073NCATS NIH HHS UL1 TR000075NCATS NIH HHS UL1 TR000093NCATS NIH HHS UL1 TR000105NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001064NCATS NIH HHS UL1 TR001420NCATS NIH HHS UL1 TR001860NCATS NIH HHS UL1 TR003167NCATS NIH HHS UM1 TR004528NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR025752NCRR NIH HHS UL1 RR025755NCRR NIH HHS UL1 RR025771NHLBI NIH HHS HHSN268200900040CNHLBI NIH HHS HHSN268200900046CNHLBI NIH HHS HHSN268200900047CNHLBI NIH HHS HHSN268200900048CNHLBI NIH HHS HHSN268200900049CNHLBI NIH HHS K24 HL166681NHLBI NIH HHS R01 HL144112NIA NIH HHS R00 AG071742NIA NIH HHS R00AG071742NIA NIH HHS R01 AG055606NIGMS NIH HHS P30 GM103337
6 · The paper itself

Abstract

backgroundThe association between subclinical cardiovascular disease (CVD) and cognitive decline in hypertensive adults and the underlying brain pathologies remain unclear. It is also undetermined whether intensifying blood pressure (BP) treatment slows down cognitive decline associated with subclinical CVD.

methodsWe conducted a post hoc analysis of the Systolic Blood Pressure Intervention Trial. Subclinical CVD at baseline was identified by elevated levels of high-sensitivity cardiac troponin T (hs-cTnT ≥ 14 ng/L) and N-terminal pro-B-type natriuretic peptide (NT-proBNP ≥ 125 pg/mL). Global cognitive function and domain-specific measures (memory, processing speed, language, and executive function) were assessed at baseline and follow-up (years 2, 4, and 6) in 2 733 participants. White matter lesions, cerebral blood flow, and brain tissue volume were assessed by MRI at baseline and year 4 in a subset of 639 participants.

resultsBoth elevated hs-cTnT and NT-proBNP levels at baseline were associated with accelerated cognitive decline across all domains after adjusting for potential confounding factors. The group with elevated levels of both cardiac biomarkers showed the fastest decline, with a larger annual decline rate of 0.033 (95% CI: 0.024-0.041) in the z-score of global cognitive function compared with the group with normal levels. Elevated levels of both biomarkers were also associated with a faster progression in white matter lesions, but not with changes in total brain tissue volume or cerebral blood flow. Intensive BP treatment did not attenuate these associations compared with standard treatment.

conclusionsSubclinical CVD may contribute to faster white matter lesion progression and accelerated cognitive decline in patients with hypertension, regardless of intensive BP treatment.

Indexed as

BrainCognitive DysfunctionHypertensionNatriuretic Peptide, BrainPeptide FragmentsTroponin TAgedAntihypertensive AgentsBiomarkersCerebrovascular CirculationFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedAntihypertensive AgentsBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponin TBlood pressure treatmentBrain pathological changesCognitive declineHypertensionSubclinical cardiovascular disease

Identifiers

PMID39774657
PMCPMC12070484

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.